After USFDA warning, Abbott Labs to stop sales of Similac Probiotic Tri-Blend product
"The product is an unapproved new drug and an unlicensed biological product being sold in violation" of regulations, the FDA said about Abbott's Similac probiotic product.;
United States: Abbott Laboratories will stop sales of its Similac Probiotic Tri-Blend product used for hospitalized preterm infants after the U.S. Food and Drug Administration issued a warning letter, the health regulator said.
In the letter, the FDA said it was concerned that preterm infants were at risk of potentially fatal diseases or infections caused by bacteria or yeast contained in the probiotics.
"The product is an unapproved new drug and an unlicensed biological product being sold in violation" of regulations, the FDA said about Abbott's Similac probiotic product.
An Abbott spokesperson said the issue pertains to Similac Probiotic Tri-Blend, which is used by fewer than 200 hospitals, and that it does not apply to any of the company's infant formula products available at retail stores.
The agency issued a similar warning to California-based Infinant Health in September.
Read also: Abbott Gets CDSCO Panel Nod To Study Antidiabetic FDC Dapagliflozin plus Metformin
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.